Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Engineering blood cells can treat brain diseases

May 13, 2021

Clene Nanomedicine presents preliminary phase II data for CNM-Au8 in ALS

May 13, 2021

Ono Pharmaceutical, Vanderbilt University present KCNT1/KCNK2 blockers

May 13, 2021

Minerva reports phase III OLE data on roluperidone for negative symptoms of schizophrenia

May 12, 2021

Alairion presents histamine H1 receptor inverse agonists and 5-HT2A receptor antagonists

May 12, 2021

Positive data presented from MAD phase I study of CTI-1601 in Friedreich's ataxia

May 12, 2021

TRPV1 antagonist SAF-312 reduces pain after photorefractive keratectomy

May 11, 2021

Preclinical data presented for the ocular anesthetic AG-920

May 10, 2021

NuBiyota starts phase II study of MET-2 in subjects with major depression

May 10, 2021

Enrollment ongoing in phase II study of JNJ-40411813 as adjunctive therapy in epilepsy

May 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...